To the Editor.
Newborn screening (NBS) for cystic fibrosis (CF) in the United States has been implemented by some states for up to a decade. However, complex technical and ethical issues still surround NBS for CF, including considerations regarding clinical benefits of early diagnosis, availability of follow-up, therapies to treat CF, and optimum screening protocols.13 Amid ongoing discussion, we conducted a survey of state programs to understand how they perform CF screening.
The National Newborn Screening & Genetics Resource Center (NNSGRC) Web site4 was used to identify those states performing CF NBS (Table 1). These 10 programs were contacted by phone or e-mail during March 2003 to learn their CF-screening protocol, and results were sent back for their review in October 2003.
|
Procedures vary by state, but the primary screening test in each program is an immunoreactive trypsinogen (IRT). Programs establish their own cutoff level, either a specified amount or a certain top percentile of the test batch. Secondary screening is implemented by states according to 2 basic laboratory protocols: IRT confirmation alone or reflex DNA screening for specific CF gene mutations. Of the 10 state programs, 3 (Colorado, Montana, and Wyoming) repeat the IRT but do not do DNA-based screening. Seven programs perform DNA analysis, with panels ranging from 1 (
F508) to
25 (those recommended by the American College of Medical Genetics and American College of Obstetricians and Gynecologists for prenatal screening5) mutations. A sweat test at CF centers is the standard diagnostic test.
NBS for CF is being implemented in varying ways and with potentially different sensitivities. For example, the Wisconsin program noted improved screening sensitivity after a change of CF protocol from 1 (
F508) to 25 (G. Hoffman PhD, written communication, 2004) mutations. How to achieve quality and equity in screening programs remains unclear. Technical issues such as if and how many mutations are to be analyzed may affect how well CF screening is implemented.
REFERENCES
This article has been cited by other articles:
![]() |
N. S. Green, S. M. Dolan, and T. H. Murray Newborn Screening: Complexities in Universal Genetic Testing Am J Public Health, November 1, 2006; 96(11): 1955 - 1959. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||